

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 21 U.S.C. §355 (n)(4)

Carol Koski, M.D.

Committees: Gastrointestinal Drugs and the Drug Safety and Risk Management
Advisory Committees

Meeting Dates: July 31, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to Biologic License Application (BLA) 125104/33, Tysabri (Natalizumab) injection, sponsored by Biogen Idec, Inc. and Elan Pharmaceuticals, a subsidiary of Elan Corporation, plc., for the proposed indication of inducing and maintaining sustained response and remission, and eliminating corticosteroid use in patients with moderately to severely active Crohn's disease with inflammation, as evidenced by elevated C-reactive protein (CRP) level or another objective marker, and the risks (including progressive multifocal leukoencephalopathy) associated with TYSABRI (natalizumab) administration, its efficacy in the treatment of moderate to severe Crohn's disease, and proposed risk management plan(s), I am eligible to receive a waiver under 21 U.S.C. §355 (n)(4). I understand that this financial interest did not require an individual waiver under 18 U.S.C. 208(b)(3) as the interest in a publicly traded security is less than \$15,000 and thus covered by a regulatory exemption issued by the Office of Government Ethics at 5 CFR 2640.202.

Type of Interest	Nature	Magnitude
Stock	Competing Firm	Valued from \$5,001 to \$25,000

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

/S/
Signature of SGE

6/20/2007
Date